New insights into the mechanisms and management of atrial fibrillation

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 9, 2002, Pages 1012-1020

  Khairy, Paul ^a,b   Nattel, Stanley ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DIGOXIN; DILTIAZEM; DOFETILIDE; ESMOLOL; FLECAINIDE; IBUTILIDE; METOPROLOL; PROCAINAMIDE; PROPAFENONE; SOTALOL; VERAPAMIL;

BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE FAILURE; HEPATITIS; HUMAN; HYPOTENSION; LUNG FIBROSIS; NEUROTOXICITY; PATHOPHYSIOLOGY; PHLEBITIS; PRACTICE GUIDELINE; QT INTERVAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SINUS ARRHYTHMIA; SINUS RHYTHM; THYROID DISEASE;

EID: 0036979895     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
2. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol 1999;84:131R-8R.
3. Kerr CR. Atrial fibrillation: extending basic science to clinical frontiers. Can J Cardiol 1997;13:1059-61.
4. Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. Am Heart J 2002; 143:519-27.
5. Sra J, Dhala A, Blanck Z, Deshpande S, Cooley R, Akhtar M. Atrial fibrillation: epidemiology, mechanisms, and management. Curr Probl Cardiol 2000;25:405-524.
6. Maglio C, Ayers G, Tidball EW, Akhtar M. Health care utilization and cost of care in patients with symptomatic atrial fibrillation. Circulation 1996;94 (Suppl):1-169.
7. Catherwood E, Fitzpatrick WD, Greenberg ML, Holzberger PT, Malenka DJ, Gerling BR, et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999;130:625-36.
8. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
9. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959;58:59-70.
10. Allessie MA, Boyden PA, Camm AJ, Kleber AG, Lab MJ, Legato MJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103:769-77.
11. Allessie MA, Konings K, Kirchhof CJ, Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol 1996;77:10A-23A.
12. Wijffels MC, Kirchhof CJ, Dorland R, Power J, Allessie MA. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997;96:3710-20.
13. Allessie MA. Atrial fibrillation-induced electrical remodeling in humans: What is the next step? Cardiovasc Res 1999;44:10-2.
14. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415 (6868):219-26.
15. Nattel S, Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000;87:440-7.
16. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res 1999;42:477-89.
17. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;81:512-25.
18. Van der Velden HM, Ausma J, Rook MB, Hellemons AJ, van Veen TA, Allessie MA, et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000;46:476-86.
19. Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997;96:4027-35.
20. Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation 1998;98:2202-9.
21. Nattel S, Li D, Yue L. Basic mechanisms of atrial fibrillation - very new insights into very old ideas. Annu Rev Physiol 2000;62:51-77.
22. Sun H, Gaspo R, Leblanc N, Nattel S. Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation 1998; 98:719-27.
23. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95.
24. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000;101:2631-8.
25. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-14.
26. Kerr CR, Boone J, Connolly SJ, Dorian P, Green M, Klein G, et al. The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. Am J Cardiol 1998;82:82N-5.
27. Paquette M, Roy D, Talajic M, Newman D, Couturier A, Yang C, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 2000;86:764-8.
28. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
29. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001;32:803-8.
30. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
31. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2001;38:1231-66.
32. Fogel RI, Evans JJ, Prystowsky EN. Utility and cost of event recorders in the diagnosis of palpitations, presyncope, and syncope. Am J Cardiol 1997;79:207-8.
33. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997;29:135-40.
34. Wattanasuwan N, Khan IA, Mehta NJ, Arora P, Singh N, Vasavada BC, et al. Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone. Chest 2001;119:502-6.
35. Wyse DG. The AFFIRM trial: main trial and substudies - what can we expect? J Interv Card Electrophysiol 2000;(Suppl 4)1:171-6.
36. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-16.
37. Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. J Am Coll Cardiol 2000;36:794-802.
38. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-20.
39. Chun JG, Brodsky MA, Allen BJ. Modern concepts of atrial fibrillation. Herz 1993;18:67-75.
40. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-62.
41. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95.
42. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675-82.
43. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-74.
44. Nattel S, Liu L, St Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998;37:627-35.
45. Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 2001;88:974-9.
46. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 1999;100:2276-81.
47. Jagasia DH, Williams B, Ezekowitz MD. Clinical implication of antiembolic trials in atrial fibrillation and role of transesophageal echocardiography in atrial fibrillation. Curr Opin Cardiol 2000;15:58-63.
48. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999;30:1223-9.
49. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998;279:1273-7.
50. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
51. Kottkamp H, Hindricks G, Breithardt G. Role of anticoagulant therapy in atrial fibrillation. J Cardiovasc Electrophysiol 1998;9:S86-96.
52. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-45.
53. Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000;31:1217-22.
54. Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ 1999;161:493-7.
55. Calkins H, Yong P, Miller JM, Olshansky B, Carlson M, Saul JP, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation 1999;99:262-70.
56. Leitch JW, Klein G, Yee R, Guiraudon G. Sinus node-atrioventricular node isolation: long-term results with the "corridor" operation for atrial fibrillation. J Am Coll Cardiol 1991;17:970-5.
57. Van Hemel NM, Defauw JJ, Guiraudon GM, Kelder JC, Jessurun ER, Ernst JM. Long-term follow-up of corridor operation for lone atrial fibrillation: evidence for progression of disease? J Cardiovasc Electrophysiol 1997;8:967-73.
58. Cox JL, Ad N, Palazzo T, Fitzpatrick S, Suyderhoud JP, DeGroot KW, et al. Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000;12:15-9.
59. Brignole M, Menozzi C, Gianfranchi L, Musso G, Mureddu R, Bottoni N, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998;98:953-60.
60. Brignole M, Menozzi C. Control of rapid heart rate in patients with atrial fibrillation: drugs or ablation? Pacing Clin Electrophysiol 1996;19:348-56.
61. Fitzpatrick AP, Kourouyan HD, Siu A, Lee RJ, Lesh MD, Epstein LM, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996;131:499-507.
62. Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001;344:1043-51.
63. Feld GK. Radiofrequency catheter ablation versus modification of the AV node for control of rapid ventricular response in atrial fibrillation. J Cardiovasc Electrophysiol 1995;6:217-28.
64. Markowitz SM, Stein KM, Lerman BB. Mechanism of ventricular rate control after radiofrequency modification of atrioventricular conduction in patients with atrial fibrillation. Circulation 1996;94:2856-64.
65. Morady F, Hasse C, Strickberger SA, Man KC, Daoud E, Bogun F, et al. Long-term follow-up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 1997;29:113-21.
66. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
67. Ho SY, Cabrera JA, Tran VH, Farre J, Anderson RH, Sanchez-Quintana D. Architecture of the pulmonary veins: Relevance to radiofrequency ablation. Heart 2001;86:265-70.
68. Gerstenfeld EP, Guerra P, Sparks PB, Hattori K, Lesh MD. Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. J Cardiovasc Electrophysiol 2001;12:900-8.
69. Guerra PG, Lesh MD. The role of nonpharmacologic therapies for the treatment of atrial fibrillation. J Cardiovasc Electrophysiol 1999;10:450-60.
70. Attuel P, Pellerin D, Mugica J, Coumel P. DDD pacing: an effective treatment modality for recurrent atrial arrhythmias. Pacing Clin Electrophysiol 1988;11:1647-54.
71. Stangl K, Seitz K, Wirtzfeld A, Alt E, Blomer H. Differences between atrial single chamber pacing (AAI) and ventricular single chamber pacing (VVI) with respect to prognosis and antiarrhythmic effect in patients with sick sinus syndrome. Pacing Clin Electrophysiol 1990;13:2080-5.
72. Daoud EG, Timmermans C, Fellows C, Hoyt R, Lemery R, Dawson K, et al. Initial clinical experience with ambulatory use of an implantable atrial defibrillator for conversion of atrial fibrillation. Metrix Investigators. Circulation 2000;102:1407-13.
73. Daubert C, Gras D, Berder V, Leclercq C, Mabo P. Permanent atrial resynchronization by synchronous bi-atrial pacing in the preventive treatment of atrial flutter associated with high degree interatrial block. Arch Mal Coeur Vaiss 1994;87:1535-46.
74. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990; 63:157-61.
75. Resnekov L, McDonald L. Electroversion of lone atrial fibrillation and flutter including haemodynamic studies at rest and on exercise. Br Heart J 1971; 33:339-50.
76. Wyse DG. Rate versus rhythm control in management of atrial fibrillation (AFFIRM), ACC Annual Scientific Session 2002, Late-Breaking Clinical Trials II; 2002 Mar 19; Atlanta (GA).
77. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80.
78. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001;89:E32-8.
79. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodelling in dogs. Circulation 1999;100:2191-7.
80. Feng J, Wible B, Li GR, Wang Z, Nattel S. Antisense oligonucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier potassium current in cultured adult human atrial myocytes. Circ Res 1997;80: 572-9.
81. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: Can mechanistic insights be used to improve AF management? Cardiovasc Res 2002;54:347-60.